Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fangfang Yan

Showing results (101-110 of 103) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 103 results.
The Journal of Clinical Investigation|January 31, 2023
Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphomaVivian Changying Jiang, Yang Liu, Junwei Lian, et al.
Experimental Hematology & Oncology|February 7, 2024
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphomaFangfang Yan, Vivian Jiang, Alexa Jordan, et al.
Blood|July 23, 2025
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphomaWei Wang, Qingsong Cai, Yang Liu, et al.
Pageof 11

Showing results (101-110 of 103) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 103 results.
The Journal of Clinical Investigation|January 31, 2023
Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphomaVivian Changying Jiang, Yang Liu, Junwei Lian, et al.
Experimental Hematology & Oncology|February 7, 2024
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphomaFangfang Yan, Vivian Jiang, Alexa Jordan, et al.
Blood|July 23, 2025
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphomaWei Wang, Qingsong Cai, Yang Liu, et al.
Pageof 11